Next Article in Journal
Mesenchymal Stem Cell Therapies Approved by Regulatory Agencies around the World
Next Article in Special Issue
Immunomodulatory, Antioxidant, and Anti-Inflammatory Activities of Green Synthesized Copper Nanoparticles for Treatment of Chronic Toxoplasma gondii Infection
Previous Article in Journal
Curcuminoid Chalcones: Synthesis, Stability, and New Neuroprotective and Sonosensitising Activities
Previous Article in Special Issue
Analysis of Giardia lamblia Nucleolus as Drug Target: A Review
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Repurposing Terfenadine as a Novel Antigiardial Compound

by
Daniel Osmar Suárez-Rico
1,
Francisco Javier Munguía-Huizar
2,
Rafael Cortés-Zárate
2,
José Manuel Hernández-Hernández
3,
Sirenia González-Pozos
4,
Armando Perez-Rangel
3 and
Araceli Castillo-Romero
2,*
1
Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Calle Sierra Mojada 950, Independencia Oriente, Guadalajara 44340, Mexico
2
Departamento de Microbiología y Patología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Sierra Mojada 950, Col. Independencia, Guadalajara 44340, Mexico
3
Departamento de Biología Celular, Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional, Av. Instituto Politécnico Nacional 2508, Col. San Pedro Zacatenco, Ciudad de Mexico 07360, Mexico
4
Unidad de Microscopía Electrónica LaNSE, Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional, Av. Instituto Politécnico Nacional 2508, Col. San Pedro Zacatenco, Ciudad de Mexico 07360, Mexico
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2023, 16(9), 1332; https://doi.org/10.3390/ph16091332
Submission received: 31 August 2023 / Revised: 16 September 2023 / Accepted: 18 September 2023 / Published: 21 September 2023
(This article belongs to the Special Issue Drug Discovery of Antiprotozoal Agents)

Abstract

:
Giardia lamblia is a highly infectious protozoan that causes giardiasis, a gastrointestinal disease with short-term and long-lasting symptoms. The currently available drugs for giardiasis treatment have limitations such as side effects and drug resistance, requiring the search for new antigiardial compounds. Drug repurposing has emerged as a promising strategy to expedite the drug development process. In this study, we evaluated the cytotoxic effect of terfenadine on Giardia lamblia trophozoites. Our results showed that terfenadine inhibited the growth and cell viability of Giardia trophozoites in a time–dose-dependent manner. In addition, using scanning electron microscopy, we identified morphological damage; interestingly, an increased number of protrusions on membranes and tubulin dysregulation with concomitant dysregulation of Giardia GiK were observed. Importantly, terfenadine showed low toxicity for Caco-2 cells, a human intestinal cell line. These findings highlight the potential of terfenadine as a repurposed drug for the treatment of giardiasis and warrant further investigation to elucidate its precise mechanism of action and evaluate its efficacy in future research.

1. Introduction

Giardia lamblia, a flagellated protozoan with ubiquitous distribution, is the causative agent of giardiasis. This parasitosis is highly infectious and difficult to eradicate. Most of the cases are asymptomatic, but symptomatic infections typically include stomach cramps, bloating, nausea, and greasy diarrhea [1,2]. Most people recover fully without any long-lasting effects, but a small percentage may experience persistent or recurring symptoms, such as the following: postinfection irritable bowel syndrome, malabsorption and nutritional deficiencies, poor cognitive function, and reactive arthritis associated with an exaggerated immunologic response [3,4]. The current treatment of giardiasis is based on 5-nitroimidazole derivatives and some benzimidazoles [5,6]. However, they cause adverse effects such as allergic reactions and severe harm including carcinogenic activity, neurotoxic effects, and hepatic failure [7,8,9,10]. The side effects, adverse drug reactions, emergence of drug resistance, and increase in therapeutic failures have stimulated an increasing demand for novel antigiardial compounds [11,12,13].
Currently, drug repurposing is a key approach in drug development, and the use of medications (approved by the FDA) with known safety profiles offers results in less time. Some examples of recent findings suggest that disulfiram, which is a drug originally developed to treat chronic alcoholism, and acetylsalicylic acid, which is widely used to reduce pain, fever, and inflammation, are highly active against Giardia trophozoites [14,15], but they are still not in clinical use. Auranofin, a drug used for rheumatoid arthritis treatment, became interesting to use for a wider variety of diseases when it was discovered to be highly effective against cancer and infectious diseases including severe acute respiratory syndrome SARS-CoV-2. In addition, as an antiparasitic drug, this gold compound has been shown to be a good candidate treatment for amebiasis and giardiasis, but the mechanism of action of this drug is still not completely understood and has many potential gastrointestinal side effects [16,17]. Previously, we showed terfenadine (Figure 1), an antihistamine drug from the piperidine family that is used for the treatment of allergic conditions, to be a promising compound against amebiasis as it affects the growth and pathogenicity of Entamoeba histolytica [18]. In G. lamblia, homology modeling and molecular docking analysis predicted 13 binding sites for terfenadine in the pore-blocking site of a putative potassium ion channel called GiK (GL50803_101194) [19]. In this study, we describe the cytotoxic effect of terfenadine on Giardia trophozoites.

2. Results

2.1. Terfenadine Inhibits Growth and Cell Viability of Giardia lamblia Trophozoites

To determine the effect of terfenadine on parasite growth, we tested terfenadine at final concentrations of 1, 2, and 3 μM. The parasites without treatment showed stable growth kinetics, and parasite numbers tended to decrease in the first 12 h after treatment with all tested concentrations of terfenadine (Figure 2A). The maximum inhibitory effects were observed with 2 and 3 μM after 48 h of incubation, resulting in 57% and 88% inhibition, respectively. Terfenadine at 3 μM exhibited a similar inhibitory effect as that of metronidazole (MTZ) 2 μM (89% and 92%, respectively), with an IC50 = 1.6 μM (Figure 2B and Table 1). Cells without treatment and those treated with dimethyl sulfoxide (DMSO) did not show any significant differences.
Viable trophozoites at the end of the terfenadine exposition periods were determined by trypan blue exclusion. As shown in Figure 2C, after 12 h of terfenadine treatment (with 1, 2, and 3 μM, respectively), only 85%, 73%, and 53% of remanent trophozoites were viable in comparison to DMSO controls. The most dramatic effect was observed with 2 and 3 μM at 48 h; only 32% and 12%, respectively, of remanent trophozoites were viable.

2.2. Terfenadine Did Not Affect Caco-2 Cells but Was Selective for Giardia

To determine the specificity of terfenadine on Giardia lamblia, the effect of terfenadine on Caco-2 cells was evaluated. Cytotoxicity assays were performed by treating Caco-2 cells with DMSO (negative control) and 1, 2, 3, 16, and 32 μM of terfenadine for 48 h and were evaluated by MTT assay. The results showed that terfenadine at 1, 2, and 3 μM had no effect on Caco-2 cells. However, at higher concentrations tested, namely, 16 and 32 μM, an evident cytotoxic effect was observed, with viability values of 38% and 23%, respectively. In addition, a CC50 16 μM and selectivity index (SI) = 10.7 were obtained (Figure 3 and Table 1).

2.3. Terfenadine Inhibited Giardia lamblia Adhesion to Caco-2 Cells

When the inhibition and viability assays were performed, the parasite’s adhesion to glass was compromised. An interaction assay demonstrated that trophozoites treated with 1, 2, and 3 μM of terfenadine for 48 h, respectively, showed a 41%, 60%, and 79% reduction in adherence to Caco-2 cells (Figure 4A). The same effect was observed when the interaction assay was performed with healthy trophozoites in the presence of terfenadine. With only 2 h of drug exposure, adherence was reduced by 6.8%, 13.4%, and 18.5% with 1, 2, and 3 μM, respectively, in comparison to the DMSO control (Figure 4B).

2.4. Terfenadine Altered the Morphology of Giardia lamblia Trophozoites

Ultrastructural changes in trophozoites after 48 h of terfenadine treatment were evaluated using scanning electron microscopy (SEM microscopy). Trophozoites treated with DMSO (negative control) presented the characteristic morphology: pyriform, ventral disc, median body, caudal zone, and flagella without any damage (Figure 5A,B). Images of trophozoites treated with terfenadine showed parasites with damage in the caudal region and loss of their pyriform shape. At 1 μM concentration, 80% of the parasite population showed damage in the ventral disc, an apparent shortening of flagella, and membrane damage (Figure 5C,D). With 2 μM, damage in the caudal region prevailed, including folding of the cell, giving the appearance of size reduction; membrane damage; and protrusions on the dorsal side of the cell. In some trophozoites, instead of a typical flagellum, an apparent extension of the cell membrane was visible, and 100% of the cells were damaged (Figure 5E,F). At 3 μM, a large amount of cellular debris was observed, and in the remaining trophozoites, structural damage was more evident, highlighting perforations in the membrane and ventral disc (Figure 5G).

2.5. Morphological Changes by Terfenadine Involved Remodeling of Tubulin on Giardia lamblia Trophozoites

On the basis of the morphological damage in trophozoites due to terfenadine, we first analyzed the distribution of tubulin, the basic constituent of the Giardia microtubular cytoskeleton. Confocal microscopy showed tubulin cytoplasmic localization, highlighting the ventral disc, flagella, and median body, in untreated and DMSO-treated trophozoites (Figure 6A,B). Parasites treated with 1 μM terfenadine began to present changes of tubulin localization and distribution. In addition, small protein aggregates, distributed randomly throughout the cell, that are associated with morphological changes were observed (Figure 6C,F). At a concentration of 2 μM, a higher number of aggregates were present, and they had a nonrandom localization; they occupied mostly the periphery and caudal region, with an apparent decrease in cytoplasmic tubulin staining (Figure 6G). At 3 μM, where there was a greater amount of destroyed cells, the remaining cells presented reduced and nonuniform tubulin staining (Figure 6H,J).

2.6. Terfenadine Caused Downreglation of Tubulin in Giardia lamblia Trophozoites

Because terfenadine caused tubulin reorganization, we explored whether there were changes in tubulin expression. Western blot analysis revealed that the amount of tubulin was decreased with all tested concentrations as compared to untreated and DMSO-treated cells. The major reduction in tubulin was observed in cells treated with 3 µM of terfenadine (Figure 7A). After densitometric analysis, the downregulations observed were 11%, 13%, and 68% with terfenadine at 1, 2, and 3 μM, respectively (Figure 7C).
To further support the above findings, RT-PCR was performed, and the results showed that α-tubulin was reduced significantly by 17%, 47%, and 67% after 48 h of terfenadine treatment at concentrations of 1, 2, and 3 μM, respectively, as compared to the DMSO control (Figure 7E).

2.7. Terfenadine Induced Alterations in GiK Expression

Molecular modeling studies suggest that GiK is a possible target of terfenadine in Giardia lamblia. Here, the expression of GiK after terfenadine treatment was analyzed by RT-PCR. RT-PCR analysis revealed that the expression of GiK was reduced by 2%, 18%, and 74% with 1, 2, and 3 μM of terfenadine, respectively, as compared to untreated and DMSO controls (Figure 8B).

3. Discussion

The protozoan Giardia lamblia, responsible for diarrheagenic disease in animals and humans, is related to increasing rates of drug resistance and treatment failures for the most used drugs, including metronidazole and albendazole [21]. Therefore, the need for new therapies is more urgent. Currently, drug repositioning is a research approach focused on identifying new uses or therapeutic applications for existing drugs instead of spending 10–15 years developing a new drug that may not be effective or that has an investment cost that may make it unaffordable to the population. Currently, some drugs, such as disulfiram, auranofin, and acetylsalicylic acid, among others, which were initially designed for different purposes, showed promising results in Giardia lamblia, which need to be confirmed in people [15,22,23]. Others yielded encouraging results in human studies, e.g., auranofin, but the mode of action of this drug is still not completely understood [12]. Previously, our group described that terfenadine, a selective histamine H1-receptor antagonist, theoretically interacts principally with hydrophobic and aromatic residues at a specific site of a putative potassium channel of Giardia lamblia (GiK) [24].
In this study, on the basis of efficacy, terfenadine was as active as MTZ with an IC50 of 1.6 μM and SI of 10.7 (Table 1). On the basis of SI, the ideal drug should have a relatively high toxic concentration and an antigiardial activity at very low concentrations. Our SI value was 10. Therefore, we can assume that terfenadine is a selected potential drug that can be further investigated. Currently, terfenadine is no longer available on the market in several countries because of its adverse effect of prolonging the electrocardiogram QT interval [25]. However, this adverse effect is related to extended use, high doses, and concurrent antifungal drug use with ketoconazole, which inhibits CYP3A4. As a result, terfenadine does not undergo hepatic metabolism [26]. The median lethal dose (LD50) of terfenadine is reported to be 5000 mg/kg in mice, which is significantly higher than the doses used in our study. In addition, dogs tolerated an oral single dose of 30 mg/kg daily for up to 2 years without any side effects. This suggests that the concentrations of terfenadine used in our study are within a safe and effective range for assessing its potential as a therapeutic agent against the parasite [27]. Furthermore, in pediatric subjects with allergic rhinitis, no serious adverse effects were reported at doses of 40 mg. These findings provide crucial insights into the drug’s safety profile when used in children [28]. Additionally, a systematic literature review included a study on terfenadine’s safety for nursing mothers. The relative infant dose for terfenadine was found to be low (0.3%), indicating minimal transfer into breast milk. This suggests that terfenadine exposure through breastfeeding is low, a vital consideration for the safety of nursing infants [29].
Regarding the effect of terfenadine on Giardia, we observed a time–dose-dependent growth inhibition from short incubation periods (12 h). Studies with other parasites such as Plasmodium yoelii [30] and Entamoeba histolytica [18] support the antiparasitic activity of terfenadine. In E. histolytica, terfenadine concentrations of 1, 2, 3, and 4 μM affected not only growth but also cell viability and phagocytosis, a fundamental process for the development and survival of this parasite. These results are in part very similar to ours.
Conversely, we evaluated the cell viability (membrane integrity) of the trophozoites that survived the treatment using the exclusion staining method [31]. An interesting finding was that parasites stained blue with an apparent normal morphology, indicating that their membrane was not intact. This was corroborated by scanning microscopy. The images showed terfenadine-exposed parasites with protrusions/blisters and perforations in the membrane. Another interesting observation was that flagella could not be observed emerging from the trophozoite body. Instead, apparent membrane projections were observed, and this dramatic change in flagella has not been previously described. Taken together, these findings justify the lack of adhesion capacity of the trophozoites to the Caco-2 cells (the main mechanism of pathogenicity of Giardia) [32], demonstrating that terfenadine not only reduces the growth and viability of the parasites but also affects their mechanism of pathogenicity.
Several studies showed the participation of peripheral vesicles in the digestion of internalized material by Giardia. For example, Benchimol and coworkers (2022) described Giardia shape changes and the presence of large vesicles when it ingested macromolecules via receptor-mediated endocytosis, and they mentioned that these large vesicles might represent a new organelle [33]. Recently, Roberta Veríssimo and collaborators (2022) showed the presence of large protrusions in the membrane due to the effect of 4-((10H-phenothiazine-10-yl)methyl)ppaa-N-hydroxybenzamide using TEM, and they demonstrated that these protrusions corresponded to large vacuoles that harbored lamellar bodies, glycogen granules, ribosomes, and some internalized flagella, indicating that the cell may be undergoing programmed cell death similar to autophagy [34]. Conversely, a previous work with lactoferrin by Hugo Aguilar-Diaz and collaborators (2017) showed the presence of blisters and perforations in the plasma membrane of Giardia with unusual aggregates, suggesting that Giardia could be undergoing programmed cell death damage [35]. In our results, the trophozoites showed large vesicles and perforations on the plasma membrane because of terfenadine treatment.
In mammalian cells, it was described that under physiological conditions, potassium channels in the cell membrane are active, allowing the efflux of potassium ions (K+) from the intracellular environment to the extracellular space. This activity helps maintain an equilibrium of electric charges and membrane potential within the cell. In response to cellular stress or ionic imbalance, such as nutrient deprivation or toxin exposure, the intracellular concentration of K+ may change. Elevated intracellular K+ levels can trigger the activation of an autophagic signaling pathway. This signaling involves the regulation of key proteins, including the inhibition of the mTOR (mammalian target of rapamycin) pathway and activation of the ULK1 (unc-51-like kinase 1) complex. Increased intracellular potassium levels can lead to the inhibition of the mTOR protein, which typically suppresses autophagy. Inhibition of mTOR alleviates its inhibitory effect on ULK1. Activation of ULK1 is critical for the initiation of phagophore formation, the membranous structure that engulfs cellular cargos targeted for autophagic degradation. With active ULK1, phagophore formation begins. This process involves the conjugation of autophagic proteins, such as LC3 (microtubule-associated protein 1 light chain 3) and Atg12, to the phagophore membrane. The degradation of cellular cargos within the autophagolysosome releases nutrients and can lead to programmed cell death (Appendix B, Figure A1) [36,37,38,39].
In Giardia, bioinformatic analysis revealed the presence of genes associated with autophagy such as TOR, S6K1, PI3K, Atg1, Atg16, Atg7, Atg8, and Atg18. The overall mechanism of autophagy begins with the formation of a phagophore. Once the autophagosome is ready, it is transferred toward the lysosome across microtubules [36,37,40]. The integrity of the tubulin cytoskeleton is necessary to control exocytosis/endocytosis events. As a result, excessive autophagy occurs in Giardia, in which the activity of ATG proteins, a group of proteins involved in phagosome formation such as LC3 (microtubule-associated protein 1A/1B light chain 3) and ATG8, is increased. These proteins coordinate the formation of the autophagosome membrane with microtubule recruitment and subsequent degradation after fusion with the lysosome [38,41,42,43].
Previously, in human cells, it was elucidated that the interaction of HERG voltage-dependent potassium channels with PiP2 helps in regulating the activity of these channels [44,45]. Currently, there is no direct evidence that shows a direct relationship between ion channels and tubulin in Giardia. However, studies such as those of Melgari, Camacho, and Vitre [46,47,48] reported a whole signaling cascade by which the dynamics of the cytoskeleton of these human cells can be modified by the alteration of an ion channel.
In this work, we observed tubulin restructuring and the deregulation of protein expression by terfenadine treatment, concomitant with the deregulation of GiK. Our results suggest Giardia programmed cell death by autophagy (Appendix C, Figure A2).

4. Materials and Methods

4.1. Cell Culture of Giardia lamblia Trophozoites and Caco-2 Cell Line

Trophozoites of Giardia lamblia (WB clone C6) were grown axenically at 37 °C in borosilicate culture tubes containing Diamond’s TYI-S-33 modified medium (Appendix A, Table A1) at pH 7.0 (supplemented with 0.5 mg/mL of bovine bile and 10% fetal bovine serum) [49]. Cultures were maintained by cell subculturing at intervals of 72 or 96 h. Briefly, trophozoites were detached by incubation in an ice-water bath for about 20 min, then 0.5–1.0 µL of the cell suspension was transferred to culture tubes filled with fresh medium and incubated at 37 °C. Human colon carcinoma cells from (Caco-2) were cultured at 37 °C in Dulbecco’s modified Eagle’s culture medium (DMEM) supplemented with 10% fetal bovine serum (FBS; Invitrogen) in a humidified atmosphere (5% CO2 and 95% air). For routine maintenance, cells were split twice a week by detachment with 0.25% trypsin–0.025% EDTA and reseeded in 25 cm2 flasks in a split ratio of 1:4. For experiments, the numbers of Caco-2 cells and trophozoites were estimated by counting in a Neubauer chamber [50].

4.2. Growth Inhibition Assay

To evaluate the effect of terfenadine on Giardia lamblia growth, 10,000 parasites/mL were grown in TYI-S-33 medium containing 1, 2, and 3 μM of terfenadine (Sigma-Aldrich St. Louis, MO, USA). Cultures were monitored at 12, 24, and 48 h. Untreated cells and dimethyl sulfoxide (0.09% DMSO, Sigma-Aldrich, Saint Louis, MO, USA), a drug diluent, were used as negative controls. Metronidazole (2 µM MTZ) was used as a positive control. After the incubation periods, cell culture tubes were cooled in an ice-water bath to release adhered trophozoites. Cell density was calculated using a Neubauer chamber. Percentages of inhibition were calculated in comparison with DMSO control.

4.3. Terfenadine Cytotoxicity Assay

The cytotoxicity of terfenadine was evaluated on the Caco-2 cell line by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, based on a reduction in MTT to purple formazan granules. The MTT assay was performed as described previously by Mossman [51], with slight adjustments. Briefly, Caco-2 cells were seeded into a 96-well plate (5000 cells/well) and grown at 37 °C in 5% CO2 for 24 h. Cells were then treated with DMSO (0.09%, the negative control) or terfenadine (1, 2, 3, 16, and 32 μM). After 24 h, the medium was removed, 100 µL of MTT reagent (0.8 mg/mL in serum-free medium) was added to each well, and the cells were incubated at 37 °C for 4 h in 5% CO2–95% air atmosphere. Next, the medium was replaced with DMSO (150 µL) to dissolve the formazan crystals, and the absorbance was measured at 570 nm on a microplate reader (Multiskan SkyHigh Microplate Spectrophotometer, A51119500C, Thermo Scientific, Waltham, MA, USA).

4.4. Selectivity Index Calculation

The calculation of 50% cytotoxicity for both Caco-2 cells (CC50 Caco-2) and Giardia lamblia (IC50 Giardia) was conducted using nonlinear regression. The selective index (SI) was calculated as follows [52]:
SI = CC50 Caco-2/IC50 Giardia lamblia

4.5. Cell Viability Assay

A dye exclusion test was used to determine the viability of trophozoites after DMSO or terfenadine treatment. Approximately 10 µL of the culture was mixed with 10 µL of trypan blue (0.4% Gibco-BRL). The number of viable and/or dead cells was determined by light microscopy and then calculated as a percentage of negative control cells.

4.6. Cell Adhesion Assay

To evaluate the possible effect of terfenadine on adhesion, Giardia trophozoites were incubated with Caco-2 intestinal cells [53]. Briefly, 1.0 × 104 cells/well were cultured in a 24-well microplate and maintained in a humidified atmosphere of 5% CO2 at 37 °C until cells reached the monolayer. The experimental conditions were as follows: (1) interaction of trophozoites previously treated with DMSO (0.09%, negative control) and terfenadine (1, 2, 3 μM) for 48 h, with Caco-2 cells, and (2) interaction of trophozoites with Caco-2 cells and terfenadine at the same time. The trophozoites were incubated with monolayers at a Caco-2 cells: Giardia lamblia trophozoites ratio of 4:1 in 1 mL of TYI-S-33 medium. After 2 h of cell interaction at 37 °C, the medium was removed, the plates were kept on ice, and wells were filled with cold phosphate-buffered saline (PBS) and placed on ice for 30 min to detach the adherent trophozoites. The numbers of adherent and nonadherent trophozoites was determined by counting in a Neubauer chamber. The effect on adherence was expressed as the percentage of adhered trophozoites in relation to the total number of cells, and the results obtained were compared with control cultures.

4.7. Scanning Electron Microscopy (SEM)

To analyze the morphology of Giardia lamblia, 10,000 parasites/mL were grown in TYI-S-33 medium containing 1, 2, or 3 μM of terfenadine or 0.09% DMSO (negative control) for 48 h. After treatment, parasites were harvested after 48 h by centrifugation (10 min at 1973× g at 4 °C), then washed twice with PBS, fixed for 1 h with 2.5% glutaraldehyde (Sigma-Aldrich, St. Louis, MO, USA) in PBS, and adhered to poly-L-lysine-coated coverslips (Sigma-Aldrich, St. Louis, MO, USA). Coverslips with parasites adhered were washed three times with PBS and postfixed with 1% OsO4 in PBS for 1 h. Next, parasites were washed three times with PBS, dehydrated in gradient of ethanol series (50–100%), and subjected to critical point drying with CO2 in a Samdry-780 dryer (Tousimis Research, Rockville, MD, USA). Finally, cells were mounted on stainless steel holders and sputter-coated with a thin layer of gold in a Denton Vacuum Desk II (Denton Vacuum, Moorestown, NY, USA). Samples were examined and photographed using an SEM JSM-6510-LV (JEOL Ltd., Tokyo, Japan).

4.8. Immunofluorescence

Parasites treated with DMSO (the negative control) or terfenadine (1, 2, 3 μM) were harvested after 48 h by centrifugation (10 min at 1973× g at 4 °C), washed twice in PBS, and allowed to attach to polyethylenimine-coated coverslips for 20 min. The coverslips were fixed with methanol–acetone (Sigma-Aldrich, St. Louis, MO, USA) in a 1:1 ratio at −20 °C for 10 min. The adhered cells were also permeabilized with 0.05% Triton X-100 (in PBS) for 30 min. After two washes with PBS, cells were incubated for 1 h with 1% bovine serum albumin (BSA) to block nonspecific binding. Next, cells were incubated with diluted 1:1000 mouse anti-α-tubulin antibody (Invitrogen, Thermo Fisher, Scientific, Waltham, MA, USA) for 1 h at room temperature. After two PBS washes, the cells were incubated with goat anti-mouse IgG and FITC conjugated (1:200 dilution, Thermo Fisher Scientific). The coverslips were washed 10 times in PBS and then mounted on microscope slides with a drop of mounting medium containing DAPI (Prolong Gold Invitrogen). The cells were analyzed using a Leica confocal microscope (Leica TCS SP8, Confocal Laser Scanning Microscope), and images were processed using Leica Lite Software.

4.9. SDS-PAGE and Western Blot Assay

4.9.1. Protein Extracts and SDS-PAGE

Cells treated with DMSO (the negative control) or terfenadine (1, 2, 3 μM) cells were harvested after 48 h and processed to obtain a total protein extract according to an earlier report [54]. Briefly, the parasites were collected by cooling and posterior centrifugation at 1973× g for 10 min at 4 °C. The cells were lysed with RIPA buffer (sodium chloride, 150 mM, Tris-HCL, 50 mM, Nonidet P-40 1%, sodium deoxycholate 0.5%, SDS 0.1%) supplemented with complete protease inhibitor (Roche), PMSF (Sigma-Aldrich St. Louis, MO, USA), and sodium orthovanadate (Sigma-Aldrich St. Louis, MO, USA) and were incubated on ice for 30 min. Protein concentration was determined using a Bradford assay (Pierce Detergent Compatible Bradford Assay, Thermo Fisher Scientific). Readings were made using a microplate reader at 595 nm (Multiskan SkyHigh Microplate Spectrophotometer, A51119500C, Thermo Scientific, Waltham, MA, USA). Protein extracts (25 µg) were separated under reducing conditions by electrophoresis (polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate, SDS-PAGE) (10%) [55]. The electrophoretic separation of the proteins was carried out at a constant voltage of 120 V for 2 h. Visualization of protein bands was carried out by incubating the gel with a Coomassie staining solution.

4.9.2. Western Blot

Following SDS-PAGE, proteins were transferred to PVDF membranes (Amersham Pharmacia Biotech, Little Chalfont, UK) at 300 A for 70 min with a Transblot apparatus (Bio-Rad, Hercules, CA, USA). After transfer, the membranes were blocked using Pierce Fast Blocking buffer solution 1X (Thermo Fisher Scientific) for 20 min. After three washes with PBS containing 0.05% Tween 20 (PBS-T), the membranes were incubated with 1:500 mouse anti-α-tubulin (Invitrogen, #13-8000, Carlsbad, CA, USA) for 2 h. Membranes were washed three times and incubated for 1 h with goat anti-mouse IgG antibody coupled to horseradish peroxidase (1:20,000) (Pierce, Waltham, MA, USA). After five 15 min washes with PBS-T, the signal was detected by chemiluminescence (ECL Immobilon Western, Millipore, Burlington, MA, USA). Taglin 1:500 was used as a protein-loading control [56]. Signals were detected using the C-Digits system. Semiquantitative determination was performed with Image Studio Digits Software version 5.2.

4.10. RT-PCR

Total RNA was obtained from trophozoites treated with DMSO (the negative control) or terfenadine (1, 2, 3 μM) using a Total RNA Purification kit (NORGEN), following the manufacturer’s instructions. cDNAs were obtained by a reverse transcriptase reaction (Maxima cDNA Synthesis Kit, Thermo Fisher Scientific) using 1 μg of RNA and Oligo dt20 primer (Integrated DNA). For RT-PCR, the primers were designed using the following GenBank Giardia sequences: GiK (GenBank accession no. XM_001709438.1) and α-tubulin (GenBank accession no. XM_001705668.1). GiK and α-Tubulin primer sequences were as follows: GiK-F 5′-GCA CTG CAG CAG GTT AAG CTA TC-3′, GiK-R 5′-GAG TCT AGA AAA TTG TTT AAA TAA ATC AAC GC-3′ tubulin-F 5′-GCA GCTGAT CTC TGG CAA GGA-3′, and tubulin-R 5′-GCG AGG GGT AGACGA CGA ACT C-3′. The expression of the abovementioned genes was normalized to the expression level of shippo 1 (GenBank accession no. XM_001708537.1) using the following primers: shippo 1-F 5′-CGT CAT CAA CAG GTC CGA-3′ and shippo 1-R 5′-CCA GCT CTC CTT GAA CAC-3′. The RT-PCR conditions included an initial denaturation at 95 °C for 2 min and 35 cycles of 95 °C for 35 s; 56 °C (tubulin), 59 °C (GiK), or 55 °C (shippo 1) for 30 s; and 72 °C for 1 min. A final extension of 7 min at 72 °C was performed.

4.11. Statistical Analysis

All experiments were performed in triplicate and repeated three different times. Data were analyzed by ANOVA and post hoc Dunnett’s multiple comparisons test. p values of ≤0.05 were considered statistically significant (GraphPad Prism version 9.0 for Windows, Software, La Jolla, CA, USA, was employed). Error bars in graphics indicate standard deviations for the experiments.

5. Conclusions

Our data support the hypothesis that terfenadine could be a promising selective candidate for the treatment of giardiasis. Further studies are necessary to establish autophagy as a possible mechanism of action of terfenadine in Giardia lamblia.

Author Contributions

Conceptualization, A.C.-R. and D.O.S.-R.; methodology, D.O.S.-R., A.C.-R., A.P.-R., F.J.M.-H. and S.G.-P.; software, D.O.S.-R. and A.C.-R.; validation, A.C.-R. and D.O.S.-R.; formal analysis, A.C.-R., D.O.S.-R., R.C.-Z., J.M.H.-H. and A.P.-R.; investigation, A.C.-R., D.O.S.-R., F.J.M.-H. and A.P.-R.; resources, A.C.-R., D.O.S.-R. and J.M.H.-H.; data curation, A.C.-R. and D.O.S.-R.; writing—original draft preparation, A.C.-R. and D.O.S.-R.; writing—review and editing, A.C.-R., D.O.S.-R., R.C.-Z., J.M.H.-H., A.P.-R. and S.G.-P.; visualization, A.C.-R. and D.O.S.-R.; supervision, A.C.-R., J.M.H.-H. and A.P.-R.; project administration, A.C.-R. and D.O.S.-R.; funding acquisition, A.C.-R. All authors have read and agreed to the published version of the manuscript.

Funding

This research was partially supported by a grant (PIN 2021-II-CUCS) from Universidad de Guadalajara.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is contained within the article.

Acknowledgments

The authors are grateful for the confocal microcopy facilities that were provided by the Confocal Microscopy Unit at the Cell Biology Department of CINVESTAV-IPN (CONAHCyT-Mexico grant: 300062); Daniel O. Suárez-Rico thanks CONAHCyT for the undergraduate scholarship (954563).

Conflicts of Interest

The authors declare no conflict of interest. Figure A1 and Figure A2 were created with BioRender software (https://biorender.com/, accessed on 10 September 2023).

Appendix A

Table A1. TYI-S-33 modified medium.
Table A1. TYI-S-33 modified medium.
D-glucoseDIBICO 2001-E
NaClSigma-Aldrich S7653
K2HPO4Sigma-Aldrich P5655
KH2PO4Sigma-Aldrich P5505
PeptoneSigma-Aldrich G8270
L-ascorbic acidSigma-Aldrich A5960
L-cysteineSigma-Aldrich C6852
Ferric ammonium citrateSigma-Aldrich F5879
Dehydrated bovine bileSigma-Aldrich B3883

Appendix B

Figure A1. Mammalian cell’s autophagy regulation pathway.
Figure A1. Mammalian cell’s autophagy regulation pathway.
Pharmaceuticals 16 01332 g0a1

Appendix C

Figure A2. Putative mechanism of action of terfenadine: induction of autophagy. Terfenadine is thought to induce autophagy by inhibiting cell membrane potassium channels, causing an intracellular potassium buildup and ionic stress. This stress, along with other cellular signals, inhibits the mTOR pathway, which typically suppresses autophagy. In response, the ULK1 complex is activated, initiating phagophore formation, the initial step in autophagosome creation. During this process, autophagic proteins like LC3 (microtubule-associated protein 1 light chain 3) and Atg12 are added to the phagophore membrane. Completed phagophores merge with lysosomes, forming autophagolysosomes where cellular contents are degraded and recycled, ultimately inducing autophagy. This represents a putative mechanism by which terfenadine triggers autophagy by affecting potassium channels and initiating a series of intracellular events.
Figure A2. Putative mechanism of action of terfenadine: induction of autophagy. Terfenadine is thought to induce autophagy by inhibiting cell membrane potassium channels, causing an intracellular potassium buildup and ionic stress. This stress, along with other cellular signals, inhibits the mTOR pathway, which typically suppresses autophagy. In response, the ULK1 complex is activated, initiating phagophore formation, the initial step in autophagosome creation. During this process, autophagic proteins like LC3 (microtubule-associated protein 1 light chain 3) and Atg12 are added to the phagophore membrane. Completed phagophores merge with lysosomes, forming autophagolysosomes where cellular contents are degraded and recycled, ultimately inducing autophagy. This represents a putative mechanism by which terfenadine triggers autophagy by affecting potassium channels and initiating a series of intracellular events.
Pharmaceuticals 16 01332 g0a2

References

  1. Lalle, M.; Hanevik, K. Treatment-refractory giardiasis: Challenges and solutions. Infect. Drug Resist. 2018, 11, 1921–1933. [Google Scholar] [CrossRef] [PubMed]
  2. Leung, A.K.C.; Leung, A.A.M.; Wong, A.H.C.; Sergi, C.M.; Kam, J.K.M. Giardiasis: An Overview. Recent Pat. Inflamm. Allergy Drug Discov. 2019, 13, 134–143. [Google Scholar] [CrossRef] [PubMed]
  3. Halliez, M.C.; Buret, A.G. Extra-intestinal and long term consequences of Giardia duodenalis infections. World J. Gastroenterol. 2013, 19, 8974–8985. [Google Scholar] [CrossRef] [PubMed]
  4. Painter, J.E.; Collier, S.A.; Gargano, J.W. Association between Giardia and arthritis or joint pain in a large health insurance cohort: Could it be reactive arthritis? Epidemiol. Infect. 2017, 145, 471–477. [Google Scholar] [CrossRef]
  5. Watkins, R.R.; Eckmann, L. Treatment of giardiasis: Current status and future directions. Curr. Infect. Dis. Rep. 2014, 16, 396. [Google Scholar] [CrossRef]
  6. Vivancos, V.; González-Alvarez, I.; Bermejo, M.; Gonzalez-Alvarez, M. Giardiasis: Characteristics, Pathogenesis and New Insights About Treatment. Curr. Top. Med. Chem. 2018, 18, 1287–1303. [Google Scholar] [CrossRef]
  7. Hernández Ceruelos, A.; Romero-Quezada, L.C.; Ruvalcaba Ledezma, J.C.; López Contreras, L. Therapeutic uses of metronidazole and its side effects: An update. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 397–401. [Google Scholar] [CrossRef]
  8. Piloiu, C.; Dumitrascu, D.L. Albendazole-Induced Liver Injury. Am. J. Ther. 2021, 28, e335–e340. [Google Scholar] [CrossRef]
  9. Tinidazole. In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury; National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, USA, 2020.
  10. Chen, Y.; Li, P.; Chen, T.; Liu, H.; Wang, P.; Dai, X.; Zou, Q. Ronidazole Is a Superior Prodrug to Metronidazole for Nitroreductase-Mediated Hepatocytes Ablation in Zebrafish Larvae. Zebrafish 2023, 20, 95–102. [Google Scholar] [CrossRef]
  11. Ansell, B.R.; McConville, M.J.; Ma’ayeh, S.Y.; Dagley, M.J.; Gasser, R.B.; Svärd, S.G.; Jex, A.R. Drug resistance in Giardia duodenalis. Biotechnol. Adv. 2015, 33, 888–901. [Google Scholar] [CrossRef]
  12. Argüello-García, R.; Leitsch, D.; Skinner-Adams, T.; Ortega-Pierres, M.G. Drug resistance in Giardia: Mechanisms and alternative treatments for Giardiasis. Adv. Parasitol. 2020, 107, 201–282. [Google Scholar] [CrossRef]
  13. Leitsch, D. Drug Resistance in the Microaerophilic Parasite Giardia lamblia. Curr. Trop. Med. Rep. 2015, 2, 128–135. [Google Scholar] [CrossRef] [PubMed]
  14. Castillo-Villanueva, A.; Rufino-Gonzalez, Y.; Mendez, S.T.; Torres-Arroyo, A.; Ponce-Macotela, M.; Martinez-Gordillo, M.N.; Reyes-Vivas, H.; Oria-Hernandez, J. Disulfiram as a novel inactivator of Giardia lamblia triosephosphate isomerase with antigiardial potential. Int. J. Parasitol. Drugs Drug Resist. 2017, 7, 425–432. [Google Scholar] [CrossRef] [PubMed]
  15. Ochoa-Maganda, V.Y.; Rangel-Castañeda, I.A.; Suárez-Rico, D.O.; Cortés-Zárate, R.; Hernández-Hernández, J.M.; Pérez-Rangel, A.; Chiquete-Félix, N.; León-Ávila, G.; González-Pozos, S.; Gaona-Bernal, J.; et al. Antigiardial Activity of Acetylsalicylic Acid Is Associated with Overexpression of HSP70 and Membrane Transporters. Pharmaceuticals 2020, 13, 440. [Google Scholar] [CrossRef] [PubMed]
  16. Tejman-Yarden, N.; Miyamoto, Y.; Leitsch, D.; Santini, J.; Debnath, A.; Gut, J.; McKerrow, J.H.; Reed, S.L.; Eckmann, L. A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia. Antimicrob. Agents Chemother. 2013, 57, 2029–2035. [Google Scholar] [CrossRef] [PubMed]
  17. Mertens, R.T.; Gukathasan, S.; Arojojoye, A.S.; Olelewe, C.; Awuah, S.G. Next Generation Gold Drugs and Probes: Chemistry and Biomedical Applications. Chem. Rev. 2023, 123, 6612–6667. [Google Scholar] [CrossRef] [PubMed]
  18. Rangel-Castañeda, I.A.; Castillo-Romero, A.; León-Ávila, G.; Zermeño-Ruiz, M.; Hernández-Hernández, J.M. Drug repositioning: Antiprotozoal activity of terfenadine against Entamoeba histolytica trophozoites. Parasitol. Res. 2021, 121, 303–309. [Google Scholar] [CrossRef]
  19. Palomo-Ligas, L.; Gutiérrez-Gutiérrez, F.; Ochoa-Maganda, V.Y.; Cortés-Zárate, R.; Charles-Niño, C.L.; Castillo-Romero, A. Identification of a novel potassium channel (GiK) as a potential drug target in Giardia lamblia: Computational descriptions of binding sites. PeerJ 2019, 7, e6430. [Google Scholar] [CrossRef]
  20. Information NCoB. Terfenadine Pubchem: NCBI. 2023. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/Terfenadine (accessed on 15 September 2023).
  21. Mørch, K.; Hanevik, K. Giardiasis treatment: An update with a focus on refractory disease. Curr. Opin. Infect. Dis. 2020, 33, 355–364. [Google Scholar] [CrossRef]
  22. Tejman-Yarden, N.; Eckmann, L. New approaches to the treatment of giardiasis. Curr. Opin. Infect. Dis. 2011, 24, 451–456. [Google Scholar] [CrossRef]
  23. Ehrenkaufer, G.; Li, P.; Stebbins, E.E.; Kangussu-Marcolino, M.M.; Debnath, A.; White, C.V.; Moser, M.S.; DeRisi, J.; Gisselberg, J.; Yeh, E.; et al. Identification of anisomycin, prodigiosin and obatoclax as compounds with broad-spectrum anti-parasitic activity. PLoS Negl. Trop. Dis. 2020, 14, e0008150. [Google Scholar] [CrossRef]
  24. Roy, M.; Dumaine, R.; Brown, A.M. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996, 94, 817–823. [Google Scholar] [CrossRef] [PubMed]
  25. Cataldi, M.; Maurer, M.; Taglialatela, M.; Church, M.K. Cardiac safety of second-generation H(1) -antihistamines when updosed in chronic spontaneous urticaria. Clin. Exp. Allergy 2019, 49, 1615–1623. [Google Scholar] [CrossRef]
  26. Honig, P.K.; Wortham, D.C.; Zamani, K.; Conner, D.P.; Mullin, J.C.; Cantilena, L.R. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993, 269, 1513–1518. [Google Scholar] [CrossRef]
  27. Gibson, J.P.; Huffmann, K.W.; Newberne, J.W. Preclinical safety studies with terfenadine. Arzneimittelforschung 1982, 32, 1179–1184. [Google Scholar] [PubMed]
  28. Simons, F.E.; Watson, W.T.; Simons, K.J. The pharmacokinetics and pharmacodynamics of terfenadine in children. J. Allergy Clin. Immunol. 1987, 80, 884–890. [Google Scholar] [CrossRef] [PubMed]
  29. Ngo, E.; Spigset, O.; Lupattelli, A.; Panchaud, A.; Annaert, P.; Allegaert, K.; Nordeng, H. Antihistamine use during breastfeeding with focus on breast milk transfer and safety in humans: A systematic literature review. Basic Clin. Pharmacol. Toxicol. 2022, 130, 171–181. [Google Scholar] [CrossRef]
  30. Singh, N.; Puri, S.K. Causal prophylactic activity of antihistaminic agents against Plasmodium yoelii nigeriensis infection in Swiss mice. Acta Trop. 1998, 69, 255–260. [Google Scholar] [CrossRef]
  31. Strober, W. Trypan Blue Exclusion Test of Cell Viability. Curr. Protoc. Immunol. 2015, 111, A3.B.1–A3.B.3. [Google Scholar] [CrossRef]
  32. Certad, G.; Viscogliosi, E.; Chabé, M.; Cacciò, S.M. Pathogenic Mechanisms of Cryptosporidium and Giardia. Trends Parasitol. 2017, 33, 561–576. [Google Scholar] [CrossRef]
  33. Benchimol, M.; Gadelha, A.P.; de Souza, W. Unusual Cell Structures and Organelles in Giardia intestinalis and Trichomonas vaginalis Are Potential Drug Targets. Microorganisms 2022, 10, 2176. [Google Scholar] [CrossRef] [PubMed]
  34. Oliveira, R.V.F.; de Souza, W.; Vögerl, K.; Bracher, F.; Benchimol, M.; Gadelha, A.P.R. In vitro effects of the 4-[(10H-phenothiazin-10-yl)methyl]-N-hydroxybenzamide on Giardia intestinalis trophozoites. Acta Trop. 2022, 232, 106484. [Google Scholar] [CrossRef] [PubMed]
  35. Aguilar-Diaz, H.; Canizalez-Roman, A.; Nepomuceno-Mejia, T.; Gallardo-Vera, F.; Hornelas-Orozco, Y.; Nazmi, K.; Bolscher, J.G.; Carrero, J.C.; Leon-Sicairos, C.; Leon-Sicairos, N. Parasiticidal effect of synthetic bovine lactoferrin peptides on the enteric parasite Giardia intestinalis. Biochem. Cell Biol. 2017, 95, 82–90. [Google Scholar] [CrossRef]
  36. Choi, S.; Houdek, X.; Anderson, R.A. Phosphoinositide 3-kinase pathways and autophagy require phosphatidylinositol phosphate kinases. Adv. Biol. Regul. 2018, 68, 31–38. [Google Scholar] [CrossRef] [PubMed]
  37. Bagchi, S.; Oniku, A.E.; Topping, K.; Mamhoud, Z.N.; Paget, T.A. Programmed cell death in Giardia. Parasitology 2012, 139, 894–903. [Google Scholar] [CrossRef] [PubMed]
  38. Abuammar, H.; Bhattacharjee, A.; Simon-Vecsei, Z.; Blastyák, A.; Csordás, G.; Páli, T.; Juhász, G. Ion Channels and Pumps in Autophagy: A Reciprocal Relationship. Cells 2021, 10, 3537. [Google Scholar] [CrossRef]
  39. Nicolau-Galmés, F.; Asumendi, A.; Alonso-Tejerina, E.; Pérez-Yarza, G.; Jangi, S.M.; Gardeazabal, J.; Arroyo-Berdugo, Y.; Careaga, J.M.; Díaz-Ramón, J.L.; Apraiz, A.; et al. Terfenadine induces apoptosis and autophagy in melanoma cells through ROS-dependent and -independent mechanisms. Apoptosis 2011, 16, 1253–1267. [Google Scholar] [CrossRef]
  40. Yichoy, M.; Duarte, T.T.; De Chatterjee, A.; Mendez, T.L.; Aguilera, K.Y.; Roy, D.; Roychowdhury, S.; Aley, S.B.; Das, S. Lipid metabolism in Giardia: A post-genomic perspective. Parasitology 2011, 138, 267–278. [Google Scholar] [CrossRef]
  41. Sarbassov, D.D.; Ali, S.M.; Kim, D.H.; Guertin, D.A.; Latek, R.R.; Erdjument-Bromage, H.; Tempst, P.; Sabatini, D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 2004, 14, 1296–1302. [Google Scholar] [CrossRef]
  42. Mackeh, R.; Perdiz, D.; Lorin, S.; Codogno, P.; Poüs, C. Autophagy and microtubules—New story, old players. J. Cell Sci. 2013, 126, 1071–1080. [Google Scholar] [CrossRef]
  43. Trisciuoglio, D.; Degrassi, F. The Tubulin Code and Tubulin-Modifying Enzymes in Autophagy and Cancer. Cancers 2021, 14, 6. [Google Scholar] [CrossRef] [PubMed]
  44. Chen, Y.; Yu, L. Recent progress in autophagic lysosome reformation. Traffic 2017, 18, 358–361. [Google Scholar] [CrossRef] [PubMed]
  45. Popova, J.S.; Greene, A.K.; Wang, J.; Rasenick, M.M. Phosphatidylinositol 4,5-bisphosphate modifies tubulin participation in phospholipase Cbeta1 signaling. J. Neurosci. 2002, 22, 1668–1678. [Google Scholar] [CrossRef]
  46. Melgari, D.; Barbier, C.; Dilanian, G.; Rücker-Martin, C.; Doisne, N.; Coulombe, A.; Hatem, S.N.; Balse, E. Microtubule polymerization state and clathrin-dependent internalization regulate dynamics of cardiac potassium channel: Microtubule and clathrin control of K(V)1.5 channel. J. Mol. Cell. Cardiol. 2020, 144, 127–139. [Google Scholar] [CrossRef]
  47. Camacho, J.; Sánchez, A.; Stühmer, W.; Pardo, L.A. Cytoskeletal interactions determine the electrophysiological properties of human EAG potassium channels. Pflug. Arch. 2000, 441, 167–174. [Google Scholar] [CrossRef] [PubMed]
  48. Vitre, B.; Coquelle, F.M.; Heichette, C.; Garnier, C.; Chrétien, D.; Arnal, I. EB1 regulates microtubule dynamics and tubulin sheet closure in vitro. Nat. Cell Biol. 2008, 10, 415–421. [Google Scholar] [CrossRef]
  49. Keister, D.B. Axenic culture of Giardia lamblia in TYI-S-33 medium supplemented with bile. Trans. R. Soc. Trop. Med. Hyg. 1983, 77, 487–488. [Google Scholar] [CrossRef]
  50. Bastidas, O. Cell Counting with Neubauer Chamber, Basic Hemocytometer Usage; Technical Note-Neubauer Chamber Cell Counting; Celeromics: Valencia, Spain, 2013; pp. 1–6. [Google Scholar]
  51. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55–63. [Google Scholar] [CrossRef]
  52. Krzywik, J.; Mozga, W.; Aminpour, M.; Janczak, J.; Maj, E.; Wietrzyk, J.; Tuszyński, J.A.; Huczyński, A. Synthesis, Antiproliferative Activity and Molecular Docking Studies of Novel Doubly Modified Colchicine Amides and Sulfonamides as Anticancer Agents. Molecules 2020, 25, 1789. [Google Scholar] [CrossRef]
  53. Rigothier, M.C.; Coconnier, M.H.; Servin, A.L.; Gayral, P. A new in vitro model of Entamoeba histolytica adhesion, using the human colon carcinoma cell line Caco-2: Scanning electron microscopic study. Infect. Immun. 1991, 59, 4142–4146. [Google Scholar] [CrossRef]
  54. Palomo-Ligas, L.; Estrada-Camacho, J.; Garza-Ontiveros, M.; Vargas-Villanueva, J.R.; Gutiérrez-Gutiérrez, F.; Nery-Flores, S.D.; Cañas Montoya, J.A.; Ascacio-Valdés, J.; Campos-Muzquiz, L.G.; Rodriguez-Herrera, R. Polyphenolic extract from Punica granatum peel causes cytoskeleton-related damage on Giardia lamblia trophozoites in vitro. PeerJ 2022, 10, e13350. [Google Scholar] [CrossRef] [PubMed]
  55. Matsumoto, H.; Haniu, H.; Komori, N. Determination of Protein Molecular Weights on SDS-PAGE. Methods Mol. Biol. 2019, 1855, 101–105. [Google Scholar] [CrossRef] [PubMed]
  56. Ward, H.D.; Lev, B.I.; Kane, A.V.; Keusch, G.T.; Pereira, M.E. Identification and characterization of taglin, a mannose 6-phosphate binding, trypsin-activated lectin from Giardia lamblia. Biochemistry 1987, 26, 8669–8675. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Chemical structure of terfenadine (α-(4-tert-butylphenyl)-4-hydroxydiphenylmethyl)-1-piperidinebutanol) [20].
Figure 1. Chemical structure of terfenadine (α-(4-tert-butylphenyl)-4-hydroxydiphenylmethyl)-1-piperidinebutanol) [20].
Pharmaceuticals 16 01332 g001
Figure 2. In vitro effect of terfenadine on Giardia lamblia trophozoites after incubation for 12, 24, and 48 h. (A) Growth kinetics, (B) percentage of growth inhibition, and (C) cell viability compared to DMSO. Data correspond to mean values ± SD of three independent experiments. ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Figure 2. In vitro effect of terfenadine on Giardia lamblia trophozoites after incubation for 12, 24, and 48 h. (A) Growth kinetics, (B) percentage of growth inhibition, and (C) cell viability compared to DMSO. Data correspond to mean values ± SD of three independent experiments. ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Pharmaceuticals 16 01332 g002
Figure 3. Dose–response curve for Caco-2 cell viability in the presence of terfenadine. Data correspond to mean values ± SD of three independent experiments. **** p < 0.0001.
Figure 3. Dose–response curve for Caco-2 cell viability in the presence of terfenadine. Data correspond to mean values ± SD of three independent experiments. **** p < 0.0001.
Pharmaceuticals 16 01332 g003
Figure 4. Percentage of adhesion of Giardia lamblia trophozoites to Caco-2 cells. Trophozoites previously exposed for 48 h to terfenadine compared to DMSO (A). Under standard assay conditions, in the presence of terfenadine from 2 h compared to DMSO control (B). Data correspond to mean values ± SD of three independent experiments. ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Figure 4. Percentage of adhesion of Giardia lamblia trophozoites to Caco-2 cells. Trophozoites previously exposed for 48 h to terfenadine compared to DMSO (A). Under standard assay conditions, in the presence of terfenadine from 2 h compared to DMSO control (B). Data correspond to mean values ± SD of three independent experiments. ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Pharmaceuticals 16 01332 g004
Figure 5. Scanning electron microscopy (SEM) micrographs of G. lamblia trophozoites after 48 h treatment with terfenadine. DMSO (A,B), 1 μM (C,D), 2 μM (E,F), and 3 μM (G). Arrowhead = damage and short flagella, asterisk = dorsal protrusions, and circle = membrane perforations. Scale bar 5 and 10 µm.
Figure 5. Scanning electron microscopy (SEM) micrographs of G. lamblia trophozoites after 48 h treatment with terfenadine. DMSO (A,B), 1 μM (C,D), 2 μM (E,F), and 3 μM (G). Arrowhead = damage and short flagella, asterisk = dorsal protrusions, and circle = membrane perforations. Scale bar 5 and 10 µm.
Pharmaceuticals 16 01332 g005
Figure 6. Confocal micrographs of Giardia lamblia trophozoites after 48 h of treatment with terfenadine. Untreated cells (A,B), DMSO (C,D), 1 μM (E,F), 2 μM (G,I), 3 μM (H,J), flagella (f), middle body (m), and (d) nuclei. Bar = 10 µm.
Figure 6. Confocal micrographs of Giardia lamblia trophozoites after 48 h of treatment with terfenadine. Untreated cells (A,B), DMSO (C,D), 1 μM (E,F), 2 μM (G,I), 3 μM (H,J), flagella (f), middle body (m), and (d) nuclei. Bar = 10 µm.
Pharmaceuticals 16 01332 g006
Figure 7. Terfenadine caused decreased protein and mRNA levels in tubulin. The amount of tubulin was analyzed by Western blotting (A). Taglin was used as a loading control (B). Semiquantitative densitometric analysis of Western blot (C). The expression of tubulin (254 bp) was analyzed by RT-PCR, and shippo-1 (107 bp) was used as an internal control (D). Semiquantitative densitometric analysis (E). ** p < 0.01, **** p < 0.0001.
Figure 7. Terfenadine caused decreased protein and mRNA levels in tubulin. The amount of tubulin was analyzed by Western blotting (A). Taglin was used as a loading control (B). Semiquantitative densitometric analysis of Western blot (C). The expression of tubulin (254 bp) was analyzed by RT-PCR, and shippo-1 (107 bp) was used as an internal control (D). Semiquantitative densitometric analysis (E). ** p < 0.01, **** p < 0.0001.
Pharmaceuticals 16 01332 g007
Figure 8. Terfenadine caused decreased mRNA levels of gik. RT-PCR analysis of the gene coding for GiK (1450 bp), and shippo-1 (107 bp) was used as an internal control (A). Semiquantitative densitometric analysis (B).** p < 0.01, **** p < 0.0001.
Figure 8. Terfenadine caused decreased mRNA levels of gik. RT-PCR analysis of the gene coding for GiK (1450 bp), and shippo-1 (107 bp) was used as an internal control (A). Semiquantitative densitometric analysis (B).** p < 0.01, **** p < 0.0001.
Pharmaceuticals 16 01332 g008
Table 1. Antigiardial cytotoxicity and selectivity index values of terfenadine.
Table 1. Antigiardial cytotoxicity and selectivity index values of terfenadine.
IC50 on GiardiaCC50 on Caco-2 CellsSelectivity Index
CC50 on Caco-2 Cells/IC50 on Giardia
1.6 μM16 μM10.7
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Suárez-Rico, D.O.; Munguía-Huizar, F.J.; Cortés-Zárate, R.; Hernández-Hernández, J.M.; González-Pozos, S.; Perez-Rangel, A.; Castillo-Romero, A. Repurposing Terfenadine as a Novel Antigiardial Compound. Pharmaceuticals 2023, 16, 1332. https://doi.org/10.3390/ph16091332

AMA Style

Suárez-Rico DO, Munguía-Huizar FJ, Cortés-Zárate R, Hernández-Hernández JM, González-Pozos S, Perez-Rangel A, Castillo-Romero A. Repurposing Terfenadine as a Novel Antigiardial Compound. Pharmaceuticals. 2023; 16(9):1332. https://doi.org/10.3390/ph16091332

Chicago/Turabian Style

Suárez-Rico, Daniel Osmar, Francisco Javier Munguía-Huizar, Rafael Cortés-Zárate, José Manuel Hernández-Hernández, Sirenia González-Pozos, Armando Perez-Rangel, and Araceli Castillo-Romero. 2023. "Repurposing Terfenadine as a Novel Antigiardial Compound" Pharmaceuticals 16, no. 9: 1332. https://doi.org/10.3390/ph16091332

APA Style

Suárez-Rico, D. O., Munguía-Huizar, F. J., Cortés-Zárate, R., Hernández-Hernández, J. M., González-Pozos, S., Perez-Rangel, A., & Castillo-Romero, A. (2023). Repurposing Terfenadine as a Novel Antigiardial Compound. Pharmaceuticals, 16(9), 1332. https://doi.org/10.3390/ph16091332

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop